

# Laurent Fauchier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6829834/publications.pdf>

Version: 2024-02-01

352  
papers

28,008  
citations

16411

64  
h-index

6818

155  
g-index

374  
all docs

374  
docs citations

374  
times ranked

19441  
citing authors

#	ARTICLE	IF	CITATIONS
1	Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 973-989.	1.3	10
2	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 70-84.	1.5	25
3	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 71-164.	0.7	370
4	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 202-210.	0.7	9
5	The prevalence of left and right bundle branch block morphology ventricular tachycardia amongst patients with arrhythmogenic cardiomyopathy and sustained ventricular tachycardia: insights from the European Survey on Arrhythmogenic Cardiomyopathy. <i>Europace</i> , 2022, 24, 285-295.	0.7	7
6	Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation. <i>Stroke</i> , 2022, 53, 497-504.	1.0	16
7	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 721-728.	0.7	12
8	Reply to "Digoxin and beta-blockers in patients with heart failure". Letter regarding the article "Clinical outcomes with digoxin vs. beta-blocker for heart rate control in permanent atrial fibrillation with heart failure". <i>European Journal of Heart Failure</i> , 2022, 24, 239-241.	2.9	0
9	Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13745.	1.7	10
10	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871.	0.7	11
11	Breast cancer and incident cardiovascular events: A systematic analysis at the nationwide level. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13754.	1.7	2
12	Yearly Incidence of Stroke and Bleeding in Atrial Fibrillation with Concomitant Hyperthyroidism: A National Discharge Database Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1342.	1.0	1
13	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	1.0	5
14	Myocardial Revascularization Strategies in ST Elevation Myocardial Infarction Without Urgent Revascularization: Insight From a Nationwide Study. <i>Mayo Clinic Proceedings</i> , 2022, , .	1.4	0
15	Comparison of Surgical Ventricular Septal Reduction to Alcohol Septal Ablation Therapy in Patients with Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2022, , .	0.7	5
16	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773.	1.7	6
17	Prognosis of Atrial Fibrillation with or without Comorbidities: Analysis of Younger Adults from a Nationwide Database. <i>Journal of Clinical Medicine</i> , 2022, 11, 1981.	1.0	1
18	Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2386-2397.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Predicting outcome after cardiac resynchronisation therapy defibrillator implantation: the cardiac resynchronisation therapy defibrillator Futility score. <i>Heart</i> , 2022, 108, 1186-1193.	1.2	4
20	Valve-in-valve transcatheter aortic valve replacement or re-surgical aortic valve replacement in degenerated bioprostheses: A systematic review and meta-analysis of short and midterm results. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 100, 122-130.	0.7	7
21	Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Internal Medicine</i> , 2022, 103, 41-49.	1.0	5
22	Mortality and Major Cardiovascular Events among Patients with Multiple Myeloma: Analysis from a Nationwide French Medical Information Database. <i>Cancers</i> , 2022, 14, 3049.	1.7	1
23	For the benefit of our patients: The possibility of performing an MRI in the presence of a cardiac implantable electronic device must be maintained. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 411-413.	0.7	0
24	Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROCC-DRT registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 1276-1285.	1.5	10
25	Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. <i>Heart</i> , 2021, 107, 1376-1382.	1.2	28
26	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 229-237.	1.8	16
27	Valve-in-valve transcatheter aortic valve implantation after failed surgically implanted aortic bioprosthesis versus native transcatheter aortic valve implantation for aortic stenosis: Data from a nationwide analysis. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 41-50.	0.7	6
28	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021, 23, 174-183.	0.7	74
29	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
30	Outcomes in patients with acute myocardial infarction and new atrial fibrillation: a nationwide analysis. <i>Clinical Research in Cardiology</i> , 2021, 110, 1431-1438.	1.5	15
31	Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 24.	2.7	19
32	Re-intervention for failed surgical aortic bioprosthesis: Remaining questions on long term outcomes and selection of patients. <i>International Journal of Cardiology</i> , 2021, 323, 242.	0.8	0
33	The Multifaceted Interplay between Atrial Fibrillation and Myocardial Infarction: A Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 198.	1.0	15
34	Timing of Coronary Revascularization and Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 484-486.	1.1	2
35	Focus on stereotactic radiotherapy: A new way to treat severe ventricular arrhythmias?. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 140-149.	0.7	2
36	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. <i>Cancer</i> , 2021, 127, 2122-2129.	2.0	45

#	ARTICLE	IF	CITATIONS
37	Risk Scores in ST-Segment Elevation Myocardial Infarction Patients with Refractory Cardiogenic Shock and Veno-Arterial Extracorporeal Membrane Oxygenation. <i>Journal of Clinical Medicine</i> , 2021, 10, 956.	1.0	5
38	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. <i>European Heart Journal</i> , 2021, 42, 2000-2011.	1.0	49
39	The ICAD score for predicting prophylactic cardioverter-defibrillator implantation following acute myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 973-979.	0.5	0
40	Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROCD-DR-Registry. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010195.	1.4	46
41	Outcomes associated with pacemaker implantation following transcatheter aortic valve replacement: A nationwide cohort study. <i>Heart Rhythm</i> , 2021, 18, 2027-2032.	0.3	9
42	Acute Dental Periapical Abscess and New-Onset Atrial Fibrillation: A Nationwide, Population-Based Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2927.	1.0	3
43	Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion. <i>Journal of the American College of Cardiology</i> , 2021, 78, 297-313.	1.2	106
44	Major Bleeding of Transjugular Native Kidney Biopsies. A French Nationwide Cohort Study. <i>Kidney International Reports</i> , 2021, 6, 2594-2603.	0.4	9
45	Clinical outcomes with digoxin vs. beta-blocker for heart rate control in permanent atrial fibrillation with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1563-1565.	2.9	4
46	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2021, 42, 3427-3520.	1.0	899
47	AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. <i>European Heart Journal</i> , 2021, 42, 4731-4739.	1.0	111
48	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. <i>Europace</i> , 2021, 23, 1873-1891.	0.7	10
49	Acute myocarditis with autoimmune features: one-year follow-up with CMR. <i>Heart and Vessels</i> , 2021, , 1.	0.5	0
50	Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus. <i>Diabetologia</i> , 2021, 64, 2602-2605.	2.9	13
51	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
52	Outcomes in patients with acute myocardial infarction and history of illicit drug use: a French nationwide analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1027-1037.	0.4	6
53	Metabolically healthy obesity and cardiovascular events: A nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2492-2501.	2.2	25
54	The Prognosis of Baseline Mitral Regurgitation in Patients with Transcatheter Aortic Valve Implantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3974.	1.0	2

#	ARTICLE	IF	CITATIONS
55	Impact of gender on relative rates of cardiovascular events in patients with diabetes. <i>Diabetes and Metabolism</i> , 2021, 47, 101226.	1.4	10
56	Outcomes Following Aortic Stenosis Treatment (Transcatheter vs Surgical Replacement) in Women vs Men (From a Nationwide Analysis). <i>American Journal of Cardiology</i> , 2021, 154, 67-77.	0.7	2
57	To the Editorâ€”Fear does not avoid the danger!. <i>Heart Rhythm</i> , 2021, 18, 161.	0.3	1
58	OUP accepted manuscript. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	1
59	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021, 19, 256.	2.3	22
60	Temporal Relationship between Atrial Fibrillation and Heart Failure Development Analysis from a Nationwide Database. <i>Journal of Clinical Medicine</i> , 2021, 10, 5101.	1.0	6
61	Management of antithrombotics in situations with a gap in evidence: A national French survey focusing on patients with coronary artery disease and atrial fibrillation. <i>International Journal of Cardiology</i> , 2021, , .	0.8	0
62	Season of Birth and Cardiovascular Mortality in Atrial Fibrillation: A Population-Based Cohort Study. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 177.	0.8	1
63	When is a wearable defibrillator indicated?. <i>Expert Review of Medical Devices</i> , 2021, 18, 51-56.	1.4	3
64	Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study. <i>Europace</i> , 2020, 22, 205-215.	0.7	12
65	2019 HRS/EHRA/APHRS/LAHRs focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Heart Rhythm</i> , 2020, 17, e220-e228.	0.3	55
66	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion â€” an update. <i>Europace</i> , 2020, 22, 184-184.	0.7	160
67	Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice. <i>Thrombosis and Haemostasis</i> , 2020, 120, 005-007.	1.8	4
68	Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 17-23.	1.4	5
69	Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis. <i>Circulation</i> , 2020, 141, 260-268.	1.6	104
70	Early mortality after implantable cardioverter defibrillator: Incidence and associated factors. <i>International Journal of Cardiology</i> , 2020, 301, 114-118.	0.8	5
71	â€”Real-worldâ€™ observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , 2020, 22, 831-832.	0.7	18
72	Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator. <i>Circulation</i> , 2020, 142, 1612-1622.	1.6	34

#	ARTICLE	IF	CITATIONS
73	Major Bleeding and Risk of Death after Percutaneous Native Kidney Biopsies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1587-1594.	2.2	49
74	Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement. <i>Journal of the American College of Cardiology</i> , 2020, 76, 489-499.	1.2	93
75	Myocardial Infarction after Kidney Transplantation: A Risk and Specific Profile Analysis from a Nationwide French Medical Information Database. <i>Journal of Clinical Medicine</i> , 2020, 9, 3356.	1.0	11
76	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2287.	1.2	0
77	How should we manage left atrial thrombosis?. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 587-589.	0.7	0
78	Risk factors and outcomes of early acute kidney injury in infective endocarditis: A retrospective cohort study. <i>International Journal of Infectious Diseases</i> , 2020, 99, 421-427.	1.5	13
79	Pacemaker Implantation After Balloon- or Self-Expandable Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2020, 9, e015896.	1.6	30
80	Ischemic Stroke in Patients With Sinus Node Disease, Atrial Fibrillation, and Other Cardiac Conditions. <i>Stroke</i> , 2020, 51, 1674-1681.	1.0	15
81	Joint Position Paper of the Working Group of Pacing and Electrophysiology of the French Society of Cardiology and the French Society of Diagnostic and Interventional Cardiac and Vascular Imaging on magnetic resonance imaging in patients with cardiac electronic implantable devices. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 473-484.	0.7	11
82	Position paper concerning the competence, performance and environment required for the practice of ablation in children and in congenital heart disease. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 492-502.	0.7	3
83	Futility Risk Model for Predicting Outcome After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020, 130, 100-107.	0.7	16
84	Response by Deharo et al to Letter Regarding Article, "Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis: Data From a Nationwide Analysis". <i>Circulation</i> , 2020, 141, e912-e913.	1.6	1
85	How to estimate the potential clinical benefit associated with left atrial appendage closure?. <i>Europace</i> , 2020, 22, 1755-1755.	0.7	2
86	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020, 195, 128-135.	0.8	3
87	The CHOICE Randomized Clinical Trial. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1609-1610.	1.1	0
88	Mortality and cardiac resynchronization therapy with or without defibrillation in primary prevention. <i>Europace</i> , 2020, 22, 1224-1233.	0.7	16
89	Incidence and outcomes of infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1368-1374.	2.8	30
90	Prognosis of Type 2 Myocardial Infarction Patients Implanted With a Prophylactic Defibrillator (from) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.7	1

#	ARTICLE	IF	CITATIONS
91	Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLoS ONE, 2020, 15, e0225301.	1.1	10
92	2019 HRS/EHRA/APHRS/LAHRs focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 135-144.	0.6	8
93	Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection. Archives of Cardiovascular Diseases, 2020, 113, 293-296.	0.7	15
94	Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients with Atrial Fibrillation: A Nationwide Analysis. Journal of Clinical Medicine, 2020, 9, 1234.	1.0	24
95	Simultaneous cardiocerebral embolization in patients with atrial fibrillation. Archives of Cardiovascular Diseases, 2020, 113, 821-827.	0.7	3
96	Outcomes in nonagenarians undergoing transcatheter aortic valve implantation: a nationwide analysis. EuroIntervention, 2020, 15, 1489-1496.	1.4	12
97	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion "an update. EuroIntervention, 2020, 15, 1133-1180.	1.4	183
98	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	0.7	72
99	Atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society. Europace, 2019, 21, 192-193.	0.7	209
100	Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation. Stroke, 2019, 50, 2469-2476.	1.0	23
101	Multisite pacing via a quadripolar lead for cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology, 2019, 56, 117-125.	0.6	4
102	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace, 2019, 21, 1603-1604.	0.7	61
103	CHEST Score and Prediction of Incident Atrial Fibrillation in Poststroke Patients: A French Nationwide Study. Journal of the American Heart Association, 2019, 8, e012546.	1.6	78
104	How to upgrade a leadless pacemaker to cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 2019, 30, 2578-2581.	0.8	0
105	Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase). Archives of Cardiovascular Diseases, 2019, 112, 523-531.	0.7	1
106	2019 HRS/EHRA/APHRS/LAHRs focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Journal of Arrhythmia, 2019, 35, 485-493.	0.5	12
107	Major Adverse Events With Percutaneous Left Atrial Appendage Closure in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 73, 2638-2640.	1.2	7
108	2019 HRS/EHRA/APHRS/LAHRs focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2019, 21, 1442-1443.	0.7	59

#	ARTICLE	IF	CITATIONS
109	Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. <i>European Heart Journal</i> , 2019, 40, 2121-2127.	1.0	29
110	How is Contact Force implemented in routine clinical practice? Results from a French National and Monaco Survey. <i>Journal of Arrhythmia</i> , 2019, 35, 238-243.	0.5	1
111	Prophylactic implantable cardioverter-defibrillator in the very elderly. <i>Europace</i> , 2019, 21, 1063-1069.	0.7	11
112	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.	0.7	47
113	Stroke and Thromboembolism in Patients With Atrial Fibrillation and Mitral Regurgitation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e006990.	2.1	17
114	Reply to the letter about the position paper concerning the competence, performance and environment required in the practice of complex ablation procedures. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 290-291.	0.7	0
115	End-of-service management of leadless cardiac pacemakers: a case report. <i>Europace</i> , 2019, 21, 1245-1245.	0.7	0
116	Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1574541.	0.8	31
117	EHRA White Paper: knowledge gaps in arrhythmia managementâ€™ status 2019. <i>Europace</i> , 2019, 21, 993-994.	0.7	40
118	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 844-845.	0.7	68
119	Management of sustained arrhythmias for patients with cardiogenic shock in intensive cardiac care units. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 781-791.	0.7	3
120	Balancing the risks of adverse events and optimal programming of implantable cardioverter-defibrillators: Authorsâ€™ reply. <i>Europace</i> , 2019, 22, 170-171.	0.7	0
121	Searching for Atrial Fibrillation Poststroke. <i>Circulation</i> , 2019, 140, 1834-1850.	1.6	184
122	Position paper concerning the competence, performance and environment required in the practice of complex ablation procedures. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 67-73.	0.7	14
123	Stroke prevention in patients with atrial flutter: many questions still unanswered. <i>Europace</i> , 2019, 21, 186-187.	0.7	3
124	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 27-36.	0.7	18
125	Editorial commentary: The CHA2DS2VASc score and its black and white items. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 392-393.	2.3	2
126	Distalâ€™ proximal delay for ablation of premature ventricular contractions. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 205-211.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death. <i>Europace</i> , 2018, 20, 65-72.	0.7	21
128	Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1072-1074.	1.1	6
129	Why and how to screen for atrial fibrillation. <i>Heart</i> , 2018, 104, 1474-1475.	1.2	3
130	Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2018, 260, 82-87.	0.8	20
131	Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 945-947.	1.8	1
132	Contemporary stroke prevention strategies in 11 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.	0.7	118
133	Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 370-379.	0.7	15
134	Antiplatelet therapy, vitamin K antagonist and low time in therapeutic range in patients with atrial fibrillation: Highway to bleed. <i>International Journal of Cardiology</i> , 2018, 252, 110-111.	0.8	0
135	Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. <i>American Heart Journal</i> , 2018, 198, 39-45.	1.2	31
136	Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1528-1536.	1.2	266
137	2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRs. <i>Europace</i> , 2018, 20, 1217-1217.	0.7	243
138	Answer to the letter of Walid Amara et al.. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 304-305.	0.7	0
139	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRs) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Heart Rhythm</i> , 2018, 15, e37-e60.	0.3	21
140	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRs) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Europace</i> , 2018, 20, 1399-1421.	0.7	75
141	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRs). <i>Europace</i> , 2018, 20, 895-896.	0.7	24
142	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
143	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
144	Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. <i>International Journal of Cardiology</i> , 2018, 260, 93-98.	0.8	15

#	ARTICLE	IF	CITATIONS
145	Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. <i>Age and Ageing</i> , 2018, 47, 9-17.	0.7	67
146	Recommendations for the implantation of leadless pacemakers from the French Working Group on Cardiac Pacing and Electrophysiology of the French Society of Cardiology. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 53-58.	0.7	15
147	Prediction of Incident Atrial Fibrillation According to Gender in Patients With Ischemic Stroke From a Nationwide Cohort. <i>American Journal of Cardiology</i> , 2018, 121, 437-444.	0.7	21
148	Benefits of an early management of palpitations. <i>Medicine (United States)</i> , 2018, 97, e11466.	0.4	7
149	Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. <i>Journal of Translational Medicine</i> , 2018, 16, 299.	1.8	11
150	Left Atrial Appendage Closure in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2806-2807.	1.2	7
151	Localization of Left Ventricular Lead Electrodes in Relation to Myocardial Scar in Patients Undergoing Cardiac Resynchronization Therapy. <i>Journal of the American Heart Association</i> , 2018, 7, e009502.	1.6	9
152	Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database. <i>Therapie</i> , 2018, 73, 449-460.	0.6	2
153	Alcohol and Cardiac Structure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1463-1465.	1.2	2
154	Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2018, 20, 1565-1565a0.	0.7	186
155	High rate of recurrence at long-term follow-up after new-onset atrial fibrillation during acute myocardial infarction. <i>Europace</i> , 2018, 20, e179-e188.	0.7	20
156	Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. <i>PLoS ONE</i> , 2018, 13, e0201517.	1.1	20
157	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 72, 474-475.	1.2	5
158	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. <i>Journal of Arrhythmia</i> , 2018, 34, 99-123.	0.5	41
159	Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 976.	1.8	52
160	Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 758-765.	0.7	4
161	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017, 19, euw242.	0.7	67
162	Temporal Trends Over a Decade of Defibrillator Therapy for Primary Prevention in Community Practice. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 666-673.	0.8	14

#	ARTICLE	IF	CITATIONS
163	Prediction of Systemic Septic Embolism in Patients With Left-Sided Infective Endocarditis. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1992-1993.	1.2	1
164	Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. <i>Advances in Therapy</i> , 2017, 34, 1283-1290.	1.3	4
165	Screening for Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 1851-1867.	1.6	453
166	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.	0.7	124
167	Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. <i>Clinical Research in Cardiology</i> , 2017, 106, 813-823.	1.5	61
168	Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the D3fibrillateur Automatique Implantable2Pr3vention Primaire registry. <i>Europace</i> , 2017, 19, 1478-1484.	0.7	33
169	PREDICTORS OF INCIDENT ATRIAL FIBRILLATION IN PATIENTS WITH ISCHEMIC STROKE: A NATIONWIDE COHORT STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 328.	1.2	0
170	INCIDENT ATRIAL FIBRILLATION ACCORDING TO GENDER IN PATIENTS WITH ISCHEMIC STROKE: A NATIONWIDE COHORT STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 367.	1.2	0
171	WHAT ARE THE DIFFERENCES IN ORAL ANTICOAGULANT TREATMENT PERSISTENCE IN NON-VALVULAR ATRIAL FIBRILLATION IN EUROPE? REAL-WORLD STUDIES IN THREE EUROPEAN COUNTRIES. <i>Journal of the American College of Cardiology</i> , 2017, 69, 498.	1.2	0
172	Predicting Clinical and Echocardiographic Response After Cardiac Resynchronization Therapy With a Score Combining Clinical, Electrocardiographic, and Echocardiographic Parameters. <i>American Journal of Cardiology</i> , 2017, 119, 1797-1802.	0.7	5
173	Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Native Heart Valves. <i>American Journal of Cardiology</i> , 2017, 119, 1854-1861.	0.7	6
174	Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study. <i>Heart Rhythm</i> , 2017, 14, 211-217.	0.3	24
175	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. <i>Advances in Therapy</i> , 2017, 34, 357-377.	1.3	14
176	Nonsustained Ventricular Tachycardia at the Time of3Implantation Predicts Appropriate Therapies on Rapid Ventricular Arrhythmia in Primary Prevention Patients With Nonischemic Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1338-1339.	1.3	6
177	Relationship of Preexisting Cardiovascular Comorbidities to Newly Diagnosed Atrial Fibrillation After Ischemic Stroke. <i>Stroke</i> , 2017, 48, 2878-2880.	1.0	12
178	Three-dimensional interlead distance predicts response and outcomes after cardiac resynchronization therapy. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 590-598.	0.7	1
179	Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Prosthetic or Bioprosthetic Heart Valves. <i>American Journal of Cardiology</i> , 2017, 120, 1884-1890.	0.7	6
180	The wearable cardioverter-defibrillator: current technology and evolving indications. <i>Europace</i> , 2017, 19, 335-345.	0.7	65

#	ARTICLE	IF	CITATIONS
181	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	0.8	83
182	Prognosis in patients with atrial fibrillation and a presumed "contemporary cause" in a community-based cohort study. <i>Clinical Research in Cardiology</i> , 2017, 106, 202-210.	1.5	24
183	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management" an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardıaca y Electrofisiologıa (SOLAECE). <i>Europace</i> , 2017, 19, 1556-1578.	0.7	186
184	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardıaca y Electrofisiologıa (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	0.7	208
185	document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardıaca y Electrofisiologıa (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	0.7	107
186	document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci3n Cardıaca y Electrofisiologıa (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	1.8	41
187	Outcomes in Guideline-Based Versus Off-Guideline Primary Prevention Implantable Cardioverter-Defibrillator Recipients. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1302-1303.	1.2	4
188	Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women"Data From a Multicenter French Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	46
189	Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators Groupe de rythmologie et stimulation cardiaque de la Soci�t� fran�aise de cardiologie et Soci�t� fran�aise de g�riatrie et g�rontologie. <i>Psychologie &amp; Neuropsychiatrie Du Vieillissement</i> , 2016, 14, 239-264.	0.2	2
190	Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?. <i>Cardiac Failure Review</i> , 2016, 2, 35.	1.2	8
191	Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1150-1158.	1.8	8
192	Prognosis in Familial Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	4
193	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA <sub>2</sub> DS <sub>2</sub> -VASc Risk Factor Be Anticoagulated?. <i>Stroke</i> , 2016, 47, 1831-1836.	1.0	59
194	Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor. <i>Chest</i> , 2016, 149, 960-968.	0.4	55
195	Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. <i>International Journal of Cardiology</i> , 2016, 217, 85-91.	0.8	33
196	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Journal of Arrhythmia</i> , 2016, 32, 1-28.	0.5	34
197	Long-Term Outcome and Valve Surgery for Infective Endocarditis in the Systematic Analysis of a Community Study. <i>Annals of Thoracic Surgery</i> , 2016, 102, 496-504.	0.7	33
198	Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low "moderate risk of stroke?. <i>European Journal of Internal Medicine</i> , 2016, 35, e9-e10.	1.0	2

#	ARTICLE	IF	CITATIONS
199	Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators: Groupe de Rythmologie et Stimulation Cardiaque de la Soci��t�� Fran��aise de Cardiologie and Soci��t�� Fran��aise de G��riatrie et G��rontologie. Archives of Cardiovascular Diseases, 2016, 109, 563-585.	0.7	19
200	Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study. International Journal of Cardiology, 2016, 221, 951-956.	0.8	3
201	Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. American Journal of Medicine, 2016, 129, 1278-1287.	0.6	139
202	Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	21
203	Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification. American Journal of Cardiology, 2016, 118, 1225-1232.	0.7	8
204	Rhythm control in atrial fibrillation. Lancet, The, 2016, 388, 829-840.	6.3	112
205	Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Scientific Reports, 2016, 6, 34357.	1.6	45
206	Response by Fauchier et al to Letter Regarding Article, "Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA <sub>2</sub> DS <sub>2</sub> -VASc Risk Factor Be Anticoagulated?" Stroke, 2016, 47, e239.	1.0	0
207	Atrial fibrillation. Nature Reviews Disease Primers, 2016, 2, 16016.	18.1	185
208	Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. Thrombosis and Haemostasis, 2016, 115, 1056-1063.	1.8	33
209	Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace, 2016, 18, 501-507.	0.7	29
210	Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. American Journal of Cardiology, 2016, 118, 700-707.	0.7	22
211	Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings. International Journal of Cardiology, 2016, 206, 89-92.	0.8	3
212	CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis. Journal of the American College of Cardiology, 2016, 67, 343-344.	1.2	11
213	Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. International Journal of Stroke, 2016, 11, 302-312.	2.9	64
214	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2016, 13, e50-e86.	0.3	197
215	Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence?. International Journal of Cardiology, 2016, 203, 987-994.	0.8	21
216	Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention. Heart Rhythm, 2016, 13, 1045-1051.	0.3	28

#	ARTICLE	IF	CITATIONS
217	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Europace</i> , 2016, 18, 159-183.	0.7	135
218	The Impact of Associated Diabetic Retinopathy on Stroke and Severe Bleeding Risk in Diabetic Patients With Atrial Fibrillation. <i>Chest</i> , 2015, 147, 1103-1110.	0.4	26
219	Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation. <i>Chest</i> , 2015, 148, 491-498.	0.4	9
220	Prediction of Nonarrhythmic Mortality in Primary Prevention Implantable Cardioverter-Defibrillator Patients With Ischemic and Nonischemic Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 29-37.	1.3	13
221	The SAME-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 657-659.	1.8	22
222	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. <i>PLoS ONE</i> , 2015, 10, e0125164.	1.1	15
223	Prognosis of silent atrial fibrillation after acute myocardial infarction at 1-year follow-up. <i>Heart</i> , 2015, 101, 864-869.	1.2	20
224	Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. <i>Open Heart</i> , 2015, 2, e000290.	0.9	44
225	History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2015, 128, 30-37.	0.6	41
226	Prognostic value of CHA <sub>2</sub> DS <sub>2</sub> -VASc score in patients with non-valvular atrial fibrillation™ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. <i>European Heart Journal</i> , 2015, 36, 1822.2-1830.	1.0	53
227	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	0.7	138
228	How to define valvular atrial fibrillation?. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 530-539.	0.7	86
229	Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. <i>International Journal of Cardiology</i> , 2015, 189, 105-107.	0.8	22
230	Effect of Age on Survival and Causes of Death After Primary Prevention Implantable Cardioverter-Defibrillator Implantation. <i>American Journal of Cardiology</i> , 2015, 115, 1415-1422.	0.7	30
231	Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision. <i>Heart</i> , 2015, 101, 832-833.	1.2	0
232	The SAME-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. <i>Europace</i> , 2015, 17, 671-673.	0.7	16
233	New insights into symptomatic or silent atrial fibrillation complicating acute myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 598-605.	0.7	14
234	Patients With Ischemic Stroke and Incident Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2432-2437.	1.0	77

#	ARTICLE	IF	CITATIONS
235	Catheter ablation for atrial fibrillation: results from the first European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA) Part II. <i>Europace</i> , 2015, 17, 1727-1732.	0.7	36
236	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
237	Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 143-150.	1.0	116
238	Relationship of the SAME-TT 2 R 2 Score to Poor-Quality Anticoagulation, Stroke, Clinically Relevant Bleeding, and Mortality in Patients With Atrial Fibrillation. <i>Chest</i> , 2014, 146, 719-726.	0.4	108
239	The atrial fibrillation epidemic: a validated diagnosis, or not?. <i>Europace</i> , 2014, 16, 1701-1702.	0.7	3
240	An atypical intracardiac mass in a 61-year-old man. <i>Heart</i> , 2014, 100, 985-985.	1.2	0
241	Programming implantable cardioverter-defibrillators in primary prevention: Higher or later. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 308-318.	0.7	4
242	Combined Score Using Clinical, Electrocardiographic, and Echocardiographic Parameters to Predict Left Ventricular Remodeling in Patients Having Had Cardiac Resynchronization Therapy Six Months Earlier. <i>American Journal of Cardiology</i> , 2014, 113, 2045-2051.	0.7	41
243	Prognosis in Patients Hospitalized With Permanent and Nonpermanent Atrial Fibrillation in Heart Failure. <i>American Journal of Cardiology</i> , 2014, 113, 1189-1195.	0.7	19
244	Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 424-432.	0.7	16
245	Prior History of Falls and Risk of Outcomes in Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. <i>American Journal of Medicine</i> , 2014, 127, 972-978.	0.6	51
246	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490
247	Outcomes After Ablation for Typical Atrial Flutter (from the Loire Valley Atrial Fibrillation Project). <i>American Journal of Cardiology</i> , 2014, 114, 1361-1367.	0.7	26
248	Incomplete recovery of mechanical and endocrine left atrial functions one month after electrical cardioversion for persistent atrial fibrillation: a pilot study. <i>Journal of Translational Medicine</i> , 2014, 12, 51.	1.8	7
249	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014, 16, 1655-1673.	0.7	105
250	Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 174, 611-617.	0.8	33
251	Efficacy of new oral anticoagulants in patients with atrial fibrillation previously treated with warfarin: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2014, 173, 122-124.	0.8	2
252	Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 549-556.	1.8	25

#	ARTICLE	IF	CITATIONS
253	A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation. <i>Chest</i> , 2014, 145, 1370-1382.	0.4	66
254	Galectin-3 in patients undergoing ablation of atrial fibrillation. <i>IJC Metabolic &amp; Endocrine</i> , 2014, 5, 56-60.	0.5	11
255	Renal Impairment and Ischemic Stroke Risk Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2079-2087.	1.2	105
256	Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2013, 167, 2682-2687.	0.8	67
257	Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical presentation: An updated meta-analysis of worldwide published data. <i>International Journal of Cardiology</i> , 2013, 168, 3027-3029.	0.8	47
258	Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 303-323.	0.7	48
259	Antiplatelet therapy strategies after percutaneous coronary intervention in patients needing oral anticoagulation. <i>Future Cardiology</i> , 2013, 9, 759-762.	0.5	0
260	Letter by MarÅn et al Regarding Article, "Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study" <i>Circulation</i> , 2013, 127, e584.	1.6	0
261	Statin therapy and atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2013, 28, 7-18.	0.8	90
262	Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants. <i>Journal of the American Heart Association</i> , 2013, 2, e000088.	1.6	4
263	Letter by May et al Regarding Article, "Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation" by Bassiouny et al.. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, e65.	2.1	2
264	Granulomatous mass adherent to a patent foramen ovale occluder. <i>European Heart Journal</i> , 2013, 34, 2251-2251.	1.0	0
265	Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 560-568.	1.8	41
266	Non-Antiarrhythmic Drugs for the Prevention of Atrial Fibrillation : ACEIs , ARBs , Statins and PUFAs. <i>Journal Medical Libanais</i> , 2013, 61, 105-108.	0.0	0
267	Assessing the Risk of Bleeding in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 941-948.	2.1	68
268	High risk in atrial fibrillation following an ablation procedure: the wide usefulness of the CHADS2 score. <i>Future Cardiology</i> , 2012, 8, 693-696.	0.5	1
269	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. <i>European Journal of Heart Failure</i> , 2012, 14, 295-301.	2.9	96
270	The evolution of infrahisian conduction time in myotonic dystrophy patients: clinical implications. <i>Heart</i> , 2012, 98, 291-296.	1.2	28



#	ARTICLE	IF	CITATIONS
271	Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction. <i>Europace</i> , 2012, 14, 968-974.	0.7	41
272	Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation. <i>Chest</i> , 2012, 141, 147-153.	0.4	96
273	New antithrombotic drugs for atrial fibrillation: caution is needed – Authors' reply. <i>Lancet</i> , The, 2012, 379, e24-e25.	6.3	1
274	Atrial flutter: Right, left, or both?. <i>Heart Rhythm</i> , 2012, 9, 844-845.	0.3	0
275	Prognosis in Patients with Atrial Fibrillation and CHA <sub>2</sub> DS <sub>2</sub> -VASc Score = 0 in a Community-Based Cohort Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 708-713.	0.8	37
276	Comparison of Frequency of Major Adverse Events in Patients With Atrial Fibrillation Receiving Bare-Metal Versus Drug-Eluting Stents in Their Coronary Arteries. <i>American Journal of Cardiology</i> , 2012, 110, 7-12.	0.7	15
277	Statin and Atrial Fibrillation: When does it work?. <i>Journal of Atrial Fibrillation</i> , 2012, 5, 443.	0.5	0
278	A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. <i>European Heart Journal</i> , 2011, 32, 1065-1076.	1.0	292
279	Apixaban after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 1844-1845.	13.9	4
280	Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. <i>International Journal of Cardiology</i> , 2011, 150, 54-58.	0.8	67
281	New antithrombotic drugs and European approval processes. <i>Lancet</i> , The, 2011, 378, 662-663.	6.3	6
282	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
283	Interventricular delay measurement using equilibrium radionuclide angiography before resynchronization therapy should be performed outside the area of segmental wall motion abnormalities. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 239-244.	3.3	3
284	Prognosis and Guideline-Adherent Antithrombotic Treatment in Patients With Atrial Fibrillation and Atrial Flutter. <i>Chest</i> , 2011, 140, 911-917.	0.4	70
285	Atrial fibrillation and renin-angiotensin-aldosterone system: believe it or not. <i>Europace</i> , 2011, 13, 297-298.	0.7	10
286	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
287	How should we treat patients with atrial fibrillation and a CHADS <sub>2</sub> score of 1?. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 111-115.	0.2	1
288	Unexpected low prevalence of atrial fibrillation in cryptogenic ischemic stroke: a prospective study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2010, 28, 101-107.	0.6	63

#	ARTICLE	IF	CITATIONS
289	Genetic Association Study Identifies HSPB7 as a Risk Gene for Idiopathic Dilated Cardiomyopathy. PLoS Genetics, 2010, 6, e1001167.	1.5	110
290	Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding. Europace, 2010, 12, 761-763.	0.7	8
291	Mortality in Patients With Atrial Fibrillation and Heart Failure. Journal of the American College of Cardiology, 2010, 55, 168.	1.2	0
292	Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thrombosis and Haemostasis, 2010, 103, 833-840.	1.8	104
293	Predictors for short-term progressive heart failure death in New York Heart Association II patients implanted with a cardioverter defibrillator—the EVADEF study. American Heart Journal, 2010, 159, 659-664.e1.	1.2	13
294	Ventricular Pacing Through Coronary Sinus in Patients With Tricuspid Prosthesis. Annals of Thoracic Surgery, 2010, 89, e51-e52.	0.7	10
295	Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart, 2010, 96, 1809-1814.	1.2	26
296	Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. European Heart Journal, 2009, 30, 2128-2136.	1.0	66
297	Comparison of Beta Blocker and Digoxin Alone and in Combination for Management of Patients With Atrial Fibrillation and Heart Failure. American Journal of Cardiology, 2009, 103, 248-254.	0.7	67
298	Incidence and predictive factors of atrial fibrillation after ablation of typical atrial flutter. Journal of Interventional Cardiac Electrophysiology, 2009, 24, 119-125.	0.6	19
299	Electrical storm reversible by isoproterenol infusion in a striking case of early repolarization. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 123-127.	0.6	21
300	Acute Myocardial Infarction Following Oral Methyl-Ergometrine Intake. Cardiovascular Toxicology, 2009, 9, 46-48.	1.1	24
301	Comparison of Degree of Stenosis and Plaque Volume for the Assessment of Carotid Atherosclerosis Using 2-D Ultrasound. Ultrasound in Medicine and Biology, 2009, 35, 1436-1442.	0.7	14
302	Impact of atrial prevention pacing on atrial fibrillation burden: Primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial. Heart Rhythm, 2009, 6, 295-301.	0.3	57
303	Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 828-835.	1.2	255
304	Implantable loop recorder for recurrent syncope: influence of cardiac conduction abnormalities showing up on resting electrocardiogram and of underlying cardiac disease on follow-up developments. Europace, 2008, 10, 477-481.	0.7	36
305	Implementation of new technologies in automatic external defibrillators using guidelines for cardiopulmonary resuscitation*. Critical Care Medicine, 2008, 36, 355-356.	0.4	0
306	Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: A meta-analysis of randomised controlled trials. European Journal of Heart Failure, 2007, 9, 1136-1139.	2.9	38

#	ARTICLE	IF	CITATIONS
307	Research in resuscitation from cardiac arrest: Where should we go from here?*. Critical Care Medicine, 2007, 35, 1436-1437.	0.4	2
308	Revascularization algorithm in acute STEMI should take into account age. Cardiovascular Revascularization Medicine, 2007, 8, 90-93.	0.3	5
309	To the Editor. Heart Rhythm, 2007, 4, 120.	0.3	1
310	Segmental Wall Motion Abnormality Analyzed by Equilibrium Radionuclide Angiography and Improvement in Ventricular Function by Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2007, 30, S58-61.	0.5	4
311	Abnormal Nocturnal Heart Rate Variability and QT Dynamics in Patients with Brugada Syndrome. PACE - Pacing and Clinical Electrophysiology, 2007, 30, S188-91.	0.5	13
312	Ventricular Tachycardia in Heterotopic Heart Transplantation. Journal of Cardiovascular Electrophysiology, 2007, 18, 457-457.	0.8	3
313	Different Criteria of Cardiac Resynchronization Therapy and Their Prognostic Value for Worsening Heart Failure or Major Arrhythmic Events in Patients With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2006, 97, 393-399.	0.7	6
314	Direct Implication of Carbon Monoxide in the Development of Heart Failure in Rats With Cardiac Hypertrophy Subjected to Air Pollution. Cardiovascular Toxicology, 2005, 5, 311-320.	1.1	10
315	Potential Cost Savings by Telemedicine-Assisted Long-Term Care of Implantable Cardioverter Defibrillator Recipients. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S255-S259.	0.5	106
316	QT dispersion in nonischemic dilated cardiomyopathy. A long-term evaluation. European Journal of Heart Failure, 2005, 7, 277-282.	2.9	15
317	CO Inhalation at Dose Corresponding to Tobacco Smoke Worsens Cardiac Remodeling after Experimental Myocardial Infarction in Rats. Toxicological Sciences, 2005, 85, 976-982.	1.4	20
318	Cholesterol levels and cholesterol lowering in idiopathic dilated cardiomyopathy. European Heart Journal, 2005, 26, 1931-1931.	1.0	4
319	World Trade Center Attack and Cardiac Events: Fact or Fear?. Journal of the American College of Cardiology, 2005, 45, 1732-1733.	1.2	1
320	Prognosis of heart failure in idiopathic dilated cardiomyopathy: has it improved in tertiary referral centres over the last 10 years?. European Heart Journal, 2004, 25, 1967-1967.	1.0	1
321	Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. European Journal of Heart Failure, 2004, 6, 181-185.	2.9	43
322	Segmental wall motion abnormalities in idiopathic dilated cardiomyopathy and their effect on prognosis. American Journal of Cardiology, 2004, 93, 1504-1509.	0.7	21
323	Depression and heart failure. Journal of the American College of Cardiology, 2004, 44, 2253-2254.	1.2	1
324	Reliability of QRS duration and morphology on surface electrocardiogram to identify ventricular dyssynchrony in patients with idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2003, 92, 341-344.	0.7	58

#	ARTICLE	IF	CITATIONS
325	Heart Rate Variability Before Ventricular Arrhythmias in Patients with Coronary Artery Disease and an Implantable Cardioverter Defibrillator. <i>Annals of Noninvasive Electrocardiology</i> , 2003, 8, 179-184.	0.5	20
326	Management of Atrial Tachyarrhythmias: Benefits of Pacemaker Diagnostics. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 233-238.	0.5	18
327	Ventricular Dyssynchrony and Risk Markers of Ventricular Arrhythmias in Nonischemic Dilated Cardiomyopathy: A Study with Phase Analysis of Angioscintigraphy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 352-356.	0.5	17
328	Therapeutic strategy in atrial fibrillation. <i>American Heart Journal</i> , 2003, 146, E1.	1.2	9
329	Heart Rate Variability in Rats Acclimatized to High Altitude. <i>High Altitude Medicine and Biology</i> , 2003, 4, 375-387.	0.5	14
330	Cardiac resynchronization in chronic heart failure: some considerations about the cost-effectiveness. <i>European Heart Journal</i> , 2003, 24, 879.	1.0	1
331	Alcoholic Cardiomyopathy and Ventricular Arrhythmias. <i>Chest</i> , 2003, 123, 1320.	0.4	19
332	Interventricular and intraventricular dyssynchrony in idiopathic dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2002, 40, 2022-2030.	1.2	189
333	Mitral valve prolapse and cardiac arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2002, 6, 129-131.	0.9	4
334	Signal-averaged electrocardiogram readings predict cardiac death and events in people with dilated cardiomyopathy. <i>Evidence-based Cardiovascular Medicine</i> , 2001, 5, 82-83.	0.0	0
335	Amazing Sinus Cardiac Arrest. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 1431-1431.	0.8	1
336	Junctional Rhythm During Slow Pathway Radiofrequency Ablation in Patients with Atrioventricular Nodal Reentrant tachycardia: Beat-to-Beat Analysis and Its Prognostic Value in Relation to Electrophysiologic and Anatomic Parameters. <i>Journal of Cardiovascular Electrophysiology</i> , 2000, 11, 405-412.	0.8	13
337	Long-term prognostic value of time domain analysis of signal-averaged electrocardiography in idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 2000, 85, 618-623.	0.7	43
338	Association between heart rate-corrected QT interval and coronary risk factors in 2,894 healthy subjects (the DESIR study). <i>American Journal of Cardiology</i> , 2000, 86, 557-559.	0.7	28
339	Fourier phase analysis of SPECT equilibrium radionuclide angiography in symptomatic patients with mitral valve prolapse without significant mitral regurgitation: Assessment of biventricular functional abnormalities suggesting a cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2000, 7, 471-477.	1.4	9
340	Delayed contraction area responsible for sustained ventricular tachycardia in an arrhythmogenic right ventricular cardiomyopathy: Demonstration by Fourier analysis of SPECT equilibrium radionuclide angiography. <i>Journal of Nuclear Cardiology</i> , 2000, 7, 539-542.	1.4	8
341	Epilepsy, Brugada syndrome and the risk of sudden unexpected death. <i>Journal of Neurology</i> , 2000, 247, 643-644.	1.8	22
342	Beta-blockers and ventricular arrhythmias in dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1993.	1.2	2

#	ARTICLE	IF	CITATIONS
343	Effect of verapamil on QT interval dynamicity. American Journal of Cardiology, 1999, 83, 807-808.	0.7	18
344	Significance of late ventricular potentials in myotonic dystrophy. American Journal of Cardiology, 1999, 84, 1099-1101.	0.7	17
345	Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 1999, 33, 1203-1207.	1.2	146
346	Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure. Cardiovascular Drugs and Therapy, 1998, 12, 483-486.	1.3	8
347	Diagnosis of arrhythmogenic right ventricular cardiomyopathy by Fourier analysis of gated blood pool single-photon emission tomography. American Journal of Cardiology, 1998, 82, 1399-1404.	0.7	30
348	Influence of duration and hour of recording on spectral measurements of heart rate variability. Journal of the Autonomic Nervous System, 1998, 73, 1-6.	1.9	17
349	Heart Rate Variability in Idiopathic Dilated Cardiomyopathy: Characteristics and Prognostic Value. Journal of the American College of Cardiology, 1997, 30, 1009-1014.	1.2	159
350	Effect of Verapamil on Heart Rate Variability in Subjects With Normal Hearts. American Journal of Cardiology, 1997, 80, 1234-1235.	0.7	9
351	Time-Domain Signal-Averaged Electrocardiogram in Nonischemic Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 231-244.	0.5	13
352	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. European Journal of Preventive Cardiology, 0, , .	0.8	3